5月13日晚间，浩欧博(688656)在回复近日收到的上交所下发的2024年年报信息披露监管工作函时表 示，公司报告期内脱敏药业务发展情况良好，并已对该业务的不确定性进行了充分的风险提示；公司脱 敏药业务相关业绩计算口径具备合理划分标准，在所有重大方面，相关费用归集、成本核算准确。 实际控制人变更为中国生物制药 2024年10月30日，浩欧博公告称，公司控股股东海瑞祥天及其一致行动人苏州外润、公司实际控制人 JOHN LI、WEIJUN LI、陈涛与辉煌润康及其一致行动人双润正安签署《股份转让协议》，约定海瑞祥 天向辉煌润康协议转让其所持公司29.99%股份，协议转让价格为33.74元/股，转让价款为6.3亿元。本次 权益变动完成后，公司控股股东将变更为辉煌润康，公司实际控制人将变更为中国生物制药有限公司。 公司同日公告，与中国生物制药有限公司、海瑞祥天及JOHN LI签署《战略合作协议》，各方将在过 敏、自免等领域，共同在脱敏药及体外诊断产品的研发、生产、销售等方面，开展积极的探索和合作。 监管函提出，公司前期发生控制权变更，方案设置业绩补偿约定，如未实现承诺业绩，由海瑞祥天等以 支付现金方式向公司补偿。年 ...

圣湘生物科技股份有限公司 二〇二五年五月 圣湘生物科技股份有限公司（688289）2024 年年度股东大会会议资料 议案三：圣湘生物科技股份有限公司关于 2025 年度董事薪酬方案的议案 ....... 12 议案五：圣湘生物科技股份有限公司关于聘任公司 2025 年度财务审计机构及内 议案六：圣湘生物科技股份有限公司关于提请股东大会授权董事会制定并执行 议案八：圣湘生物科技股份有限公司关于 2025 年度监事薪酬方案的议案 ....... 21 议案九：圣湘生物科技股份有限公司关于增资湖南圣维鲲腾生物科技有限公司暨 圣湘生物科技股份有限公司（688289）2024 年年度股东大会会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东大会规则》以及 《圣湘生物科技股份有限公司章程》 （以下简称"《公司章程》"） 《圣湘生物科技 股份有限公司股东大会议事规则》等相关规定，圣湘生物科技股份有限公司（以 下简称"公司"或"圣湘生物"）特制定 2024 年年度 ...

Core Viewpoint - The integration of AI in the medical imaging sector is transforming the industry, making AI an essential tool for clinical work and significantly enhancing diagnostic efficiency and capabilities [3][5][17]. Group 1: AI's Role in Medical Imaging - AI has become a necessity in the medical field, particularly in the 500 billion yuan medical imaging market, with over one-third of clinical staff in China using AI tools [3][5]. - The COVID-19 pandemic accelerated the adoption of AI in medical imaging, leading to a resurgence in AI product development and a significant increase in regulatory approvals for AI-related medical devices [5][10]. - Major medical device companies, such as United Imaging and GE Healthcare, are actively developing AI imaging products, indicating a shift towards an integrated ecosystem in medical AI [6][10]. Group 2: Market Dynamics and Growth - The global medical imaging market is projected to exceed 50 billion USD by 2024, with a compound annual growth rate (CAGR) of over 10% in China from 2019 to 2023 [10][12]. - Domestic brands are increasingly capturing market share in high-end medical imaging equipment, with significant advancements in technology leading to the introduction of innovative products [12][14]. - The competitive landscape is changing, with local companies like United Imaging achieving substantial market shares in various imaging modalities, challenging the dominance of established global players [12][14]. Group 3: Efficiency and Diagnostic Capabilities - AI has dramatically improved diagnostic efficiency, reducing the time required for procedures and enhancing the accuracy of diagnoses for complex conditions [17][18]. - The integration of AI allows for the use of less expensive imaging modalities, such as CT, to replace more costly procedures like PET, significantly lowering healthcare costs [18][20]. - The implementation of AI in imaging has improved the interoperability of medical data, facilitating better patient care and operational efficiency in hospitals [20][21]. Group 4: Future Trends and Challenges - The future of medical imaging is expected to focus on integrated diagnostic and therapeutic approaches, with AI playing a crucial role in personalized medicine [25][26]. - The healthcare sector is facing challenges such as regulatory hurdles, market competition, and the need for technological advancements to keep pace with AI developments [28][29]. - Despite the rapid growth of AI in healthcare, the industry must address issues related to data security, clinical applicability, and the integration of AI into existing workflows [28][29].

Core Viewpoint - AI has become an essential tool in the medical imaging sector, significantly impacting the $500 billion market and transforming operational processes in hospitals [1][6]. Group 1: AI Integration in Medical Imaging - Over one-third of clinical healthcare workers in China are using AI tools, surpassing the global average of 26% [1]. - AI has been integrated into 9 out of 12 processes in radiation therapy at Sun Yat-sen University Cancer Center, with the remaining processes automated [1]. - The COVID-19 pandemic has accelerated the adoption of AI in medical imaging, leading to a resurgence in AI product development and potential insurance support [2]. Group 2: Market Dynamics and Growth - The global medical imaging market is projected to exceed $50 billion by 2024, with a compound annual growth rate (CAGR) of over 10% in China from 2019 to 2023, potentially reaching 130 billion yuan [6][8]. - As of 2024, over 160 AI products have received regulatory approval in China, primarily related to imaging examinations [3]. - Major medical device companies are increasingly entering the AI medical imaging space, with companies like United Imaging and GE Healthcare leading the charge [3][10]. Group 3: Competitive Landscape - The traditional market has been dominated by major players like GE, Philips, and Siemens, which hold 90% of the global market share [7]. - Domestic brands are making significant strides, with several achieving top positions in various imaging device categories, such as DR and CT machines [8][10]. - The competitive landscape is shifting as domestic companies innovate and introduce advanced imaging technologies, challenging the established giants [7][10]. Group 4: Technological Advancements and Efficiency - AI has drastically improved diagnostic efficiency, reducing the time for radiation therapy from weeks to just 24 minutes [13]. - AI-enabled devices can now diagnose conditions previously requiring more expensive imaging techniques, such as PET scans, using standard MRI machines [14][15]. - The integration of AI in imaging is enhancing the quality of diagnostics, allowing for clearer images with lower radiation doses [17]. Group 5: Future Trends and Opportunities - The trend towards integrated diagnostic and treatment solutions is emerging, with imaging becoming a critical component of therapeutic processes [23]. - The development of AI-driven medical models is expected to reshape healthcare delivery, making it more efficient and accessible [26]. - The push for data sharing and interoperability in medical imaging is likely to create new opportunities for domestic companies in the evolving landscape [27].

Core Viewpoint - The company, Shengxiang Biotechnology, reported steady growth in its financial performance for 2024 and Q1 2025, with significant increases in revenue and net profit, alongside strategic acquisitions to enhance its market position in the life sciences sector [1][5]. Financial Performance - In 2024, the company achieved a revenue of 1.458 billion yuan and a net profit of 276 million yuan, both meeting expectations; the non-recurring net profit increased by 182% year-on-year [1]. - For Q1 2025, the company reported a revenue of 475 million yuan, a 22% year-on-year increase, and a net profit of approximately 91.74 million yuan, up 13% [1][5]. - The company plans to distribute a cash dividend of 2.75 yuan per 10 shares, totaling around 158 million yuan, raising the total dividend for 2024 to over 300 million yuan [1]. Strategic Acquisitions - In 2025, the company initiated a series of acquisitions, including an 807.5 million yuan purchase of 100% equity in Zhongshan Haiji, entering the biopharmaceutical growth hormone sector [5][6]. - The company also invested 75.6 million yuan for a 54% stake in Hong'an Jiyuan and 130 million yuan in Zhenmai Biotechnology to enhance its capabilities in blood cell testing and gene sequencing [6]. - These acquisitions are supported by a strong cash flow, with a net cash flow from operating activities of 274 million yuan in 2024, a 530.34% increase year-on-year [6]. Technological Advancements - In 2024, the company invested 361 million yuan in R&D, a 53% increase, representing about 25% of its revenue, and obtained over 200 new domestic and international certifications and patents [2]. - The company made significant progress in key areas such as respiratory diseases, maternal and child health, and blood source testing, with new products launched and certifications obtained [2][3]. - The company is also focusing on AI applications in healthcare, developing a smart infectious disease system that integrates cloud, IoT, big data, and AI technologies for automated detection and monitoring [3][4]. Market Expansion and Service Model - Shengxiang Biotechnology is establishing a comprehensive medical service system that integrates hospitals, communities, and home care to enhance primary healthcare capabilities [4]. - The company has launched home testing services for respiratory pathogens in multiple provinces, promoting an "Internet + Healthcare" service model [4]. - Plans for 2025 include further international market investments and a commitment to localize operations while sharing Chinese experiences along the Belt and Road Initiative [6].

Core Viewpoint - The life science industry is experiencing new development opportunities driven by technological innovation and industry integration, with Shengxiang Biology establishing a solid foundation for growth through an efficient collaborative system and innovation-driven technological breakthroughs [1] Group 1: Company Overview - Shengxiang Biology is a provider of integrated diagnostic solutions, focusing on self-innovated gene technology, in vitro diagnostic reagents, instruments, third-party medical testing services, and biopharmaceuticals [2] - The company is transitioning towards becoming a leading international player in the life science sector [2] Group 2: Operational Efficiency - The company has established a matrix management system with vertical production lines in various fields, enabling deep collaboration across R&D, production, marketing, and technical services [2] - A rapid nucleic acid testing solution for respiratory diseases has been developed, allowing for quick detection of common flu-like cases within 40 minutes [2] Group 3: Technological Innovation - Shengxiang Biology's digital infectious disease system has been approved for a national digital transformation project, enhancing management efficiency and enabling multiple AI+ medical business scenarios [3] - The company has developed a comprehensive cervical cancer prevention product matrix and has achieved international leading performance in blood screening nucleic acid detection products [3][4] Group 4: R&D Investment - The company invests approximately 25% of its revenue in R&D, with 2024 R&D expenditure reaching 361 million yuan, a 53.36% increase year-on-year [4] - Shengxiang Biology has obtained nearly 1,800 domestic and international registrations and approvals, with over 1,400 active patents globally [4] Group 5: Customer-Centric Innovation - The company has established a multi-dimensional innovation system by collaborating with top hospitals and disease control centers to address clinical needs [5] - A comprehensive health service system has been developed, integrating R&D, production, and application across various regions [5] Group 6: Industry Ecosystem - Shengxiang Biology aims for diversified and international development, focusing on key technological innovations and market resource complementarity [6] - The company is enhancing its international strategy by optimizing product combinations and market strategies based on local conditions [6] Group 7: Integrated Diagnostic Layout - The company's integrated diagnostic layout focuses on in vitro diagnostics and biomanufacturing, with advancements in immunology, sequencing, and smart technologies [7] - Strategic investments in companies like QuantuMDx and First Light Diagnostics are accelerating the industrial transformation process [7]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 名额有限 三、团队科研成果的转化案例分享 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月19日，思宇MedTech和Medtec China联合主办的 2025医疗器械研发论坛 上， 北京航空航天大学生物与医学工程学院教授、博士生导师牛旭锋 ，分享了题为 《生物医用材料创新如何推动植入介入器械的发展》 的精彩内容。 思宇MedTech提炼分享要点回顾如下，希望对医疗器械行业读者有所启发。 一、医疗器械与生物医用材料的现状分析 牛教授首先介绍了医疗器械行业的发展背景，强调医学与工程技术深度融合的重要性。 二、生物医用材料的应用方向和市场需求 牛教授重点介绍了团队的三个具体转化案例： 1、药物载体的设计与应用： 2、诊疗一体化柔性电极： 分析指出中国医疗器械产业规模与国际对比仍有差距，特别是国内医疗器械的药械比明 显低于发达国家，说明高端医疗器械国产替代空间巨大。 生物医用材料是医疗器械领域的关键组成部分，主要包括四类材料：医用金属材料、无 机非金属材料、高分子材料及复合材料。 牛教授指出，目前国内 ...